Xilio Therapeutics annual stock-based compensation
2020
2021
2022
2023
2024
2025
Xilio Therapeutics Stock-Based Compensation Growth & History (XLO)
Xilio Therapeutics's stock-based compensation was $6.9M for fiscal 2025.
View full Xilio Therapeutics company overviewXilio Therapeutics annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $6.9M | $505,000 | +7.85% |
| 2024 | 2024-12-31 | $6.4M | −$948,000 | −12.84% |
| 2023 | 2023-12-31 | $7.4M | −$1.0M | −12.37% |
| 2022 | 2022-12-31 | $8.4M | $3.5M | +69.91% |
| 2021 | 2021-12-31 | $5.0M | $3.7M | +282.56% |
| 2020 | 2020-12-31 | $1.3M | — | — |
Xilio Therapeutics quarterly stock-based compensation
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1.6M | $247,000 | +18.28% |
| Q1 2026 | 2026-03-31 | $2.2M | $676,000 | +44.04% |
| Q4 2025 | 2025-12-31 | $2.9M | $1.4M | +93.27% |
| Q3 2025 | 2025-09-30 | $1.1M | −$451,000 | −28.65% |
| Q2 2025 | 2025-06-30 | $1.4M | −$160,000 | −10.59% |
| Q1 2025 | 2025-03-31 | $1.5M | −$298,000 | −16.26% |
| Q4 2024 | 2024-12-31 | $1.5M | −$414,000 | −21.45% |
| Q3 2024 | 2024-09-30 | $1.6M | −$287,000 | −15.42% |
| Q2 2024 | 2024-06-30 | $1.5M | −$289,000 | −16.06% |
| Q1 2024 | 2024-03-31 | $1.8M | $42,000 | +2.35% |
| Q4 2023 | 2023-12-31 | $1.9M | $115,000 | +6.34% |
| Q3 2023 | 2023-09-30 | $1.9M | −$10,000 | −0.53% |
| Q2 2023 | 2023-06-30 | $1.8M | −$909,000 | −33.55% |
| Q1 2023 | 2023-03-31 | $1.8M | −$238,000 | −11.73% |
| Q4 2022 | 2022-12-31 | $1.8M | −$256,000 | −12.36% |
| Q3 2022 | 2022-09-30 | $1.9M | $780,000 | +71.49% |
| Q2 2022 | 2022-06-30 | $2.7M | $1.7M | +170.36% |
| Q1 2022 | 2022-03-31 | $2.0M | $1.2M | +155.54% |
| Q4 2021 | 2021-12-31 | $2.1M | — | — |
| Q3 2021 | 2021-09-30 | $1.1M | $408,000 | +59.74% |
| Q2 2021 | 2021-06-30 | $1.0M | — | — |
| Q1 2021 | 2021-03-31 | $794,000 | — | — |
| Q3 2020 | 2020-09-30 | $683,000 | — | — |
Xilio Therapeutics stock-based compensation trends
Over the last five fiscal years, Xilio Therapeutics's stock-based compensation increased from $1.3M to $6.9M, a change of $5.6M. The latest reported quarter, Q2 2026, shows $1.6M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Xilio Therapeutics source filings ↗